What's Happening?
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of 12 new medicines during its February 2026 meeting. Among these is mCombriax, the first combined mRNA vaccine for COVID-19 and seasonal
influenza, aimed at individuals aged 50 and older. The committee also recommended Ojemda for paediatric low-grade glioma and Onerji for advanced Parkinson's disease. Additionally, Xolremdi received a positive opinion for WHIM syndrome, a rare immune disorder. The CHMP also adopted positive opinions for six biosimilar medicines, including treatments for diabetes and rheumatoid arthritis. However, the committee recommended against granting marketing authorisation for Daybu, intended for Rett syndrome, and Iloperidone for schizophrenia.
Why It's Important?
The approval of these new medicines, particularly the combined mRNA vaccine, represents a significant advancement in public health, potentially reducing the burden of COVID-19 and influenza. The positive opinions for treatments of rare diseases and chronic conditions highlight ongoing efforts to address unmet medical needs. The decision against Daybu and Iloperidone underscores the rigorous evaluation process to ensure safety and efficacy. These developments could influence pharmaceutical markets and healthcare policies, impacting patients, healthcare providers, and the pharmaceutical industry.
